Elbion Ag

Biotie Therapies Corporation

Meda Pharma Gmbh & Co. Kg

Hildegard Kuss

Ute Egerland

Chris Rundfeldt

Norbert Höfgen

Emmanuel Polymeropoulos

Stefan Szelenyi

Thomas Kronbach

Degenhard Marx

Karin Steinike

Rudolf Schindler

Sabine Heer

Matthias Olbrich

Istvan Szelenyi

Juergen Engel

Helge Hartenhauer

Regina Draheim

Nobert Höfgen

Katrin Bernoester

Antje Gasparic

Norbert Hofgen

The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.

7-azaindoles and the use thereof as therapeutic agents

7-azaindoles inhibit phosphodiesterase 4 (PDE4). Methods for preparing these compounds and methods of treating arthritis and other conditions with the compounds are also provided.

7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them

The invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one &#x3b2;adrenoceptor agonist for the simultaneous, sequential or separate treatment of allergies and/or airway disorders, medicaments comprising the combination, processes for the production of such medicaments and the use of the novel combination for the production of medicaments for the simultaneous, sequential or separate treatment of allergies and/or airway disorders.

[object Object]

7-azaindoles inhibit phosphodiesterase 4 (PDE4). Methods for preparing these compounds are also provided.

The present invention is directed to the prevention, reversal and medical treatment of lower urinary tract dysfunction including bladder instability and other related diseases as described below including urinary flow problems, urgency and incontinence as a result of prostate hyperplasia (BPH) and to the prevention, reversal and medical treatment of irritable bowl syndrome (IBS) with special focus on the diarrhea-predominant and mixed diarrhea-constipation type IBS, both in human beings and animals.

Use of the non-opiate analgesic drug flupirtine for the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowel syndrome

The invention relates to new 7-azaindoles, their use as inhibitors of phosphodiesterase 4 and to methods for their synthesis.

7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same

The invention relates to substituted 4- or/and 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 4 activity in immunocompetent cells (e.g. macrophages and lymphocytes).

Hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them

The invention relates to substituted 4-, 6- or 7-hydroxyindoles with N-oxide groups, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.

Growing community of inventors

Dresden, Germany

Hildegard Kuss